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An In Vitro Fertilization Clinic Perspective
Manuel Viotti,1,2,* Andrea R. Victor,1,3 Darren K. Grifﬁn,3 Jason S. Groob,4 Alan J. Brake,1 Christo G. Zouves,1,2
and Frank L. Barnes1,2
Abstract
Germline genome editing (GGE) holds the potential to mitigate or even eliminate human heritable genetic
disease, but also carries genuine risks if not appropriately regulated and performed. It also raises fears in
some quarters of apocalyptic scenarios of designer babies that could radically change human reproduction.
Clinical need and the availability of alternatives are key considerations in the ensuing ethical debate. Writing
from the perspective of a fertility clinic, we offer a realistic projection of the demand for GGE. We lay out a
framework proposing that GGE, hereditary genetic disorders, and in vitro fertilization are fundamentally
entwined concepts. We note that the need for GGE to cure heritable genetic disease is typically grossly over-
estimated, mainly due to the underappreciated role of preimplantation genetic testing. However, we might
still ﬁnd applications for GGE in the correction of chromosomal abnormalities in early embryos, but techniques
for that purpose do not yet exist.
Introduction
The advent of genome editing using CRISPR-based tech-
nologies is generating tremendous enthusiasm within
both the medical and public domains regarding the poten-
tial to cure the *6,000 known human genetic disorders
that afflict up to*12% of the world’s population.1,2
An important distinction should be drawn between
germline genome editing (GGE) and somatic gene ther-
apy. GGE could be used to modify all cells in the future
organism and its offspring by targeting sperm, egg, or in
most cases the fertilized zygote. The most likely scenario
for the application of GGE is in preventing the transmis-
sion of inheritable genetic mutation(s), which would de-
pend on prior knowledge of a genetic disorder. In the
absence of a known disorder, a zygote is presumed
healthy. However, mutations that arise de novo during
embryogenesis are typically not detected until prenatal
testing, during birth, or later in life, and consideration
of somatic gene therapy becomes relevant to cure the in-
dividual.
In this article, writing from the perspective of the fer-
tility clinic, we analyze the potential demand for GGE
based on medical need, and explore the use of genetic
testing in embryos as an alternative.
In Vitro Fertilization is a Must for GGE
In practice, GGE necessitates in vitro fertilization (IVF)
laboratory techniques to provide access to the sperm,
egg, and early embryos. Successful fertilization of an
egg results from either insemination with several tens
of thousands prepared spermatozoa or after intracytoplas-
mic sperm injection (ICSI) when a single sperm is
injected directly into the oocyte with glass micropipettes.
Both techniques result in an embryo that is typically cul-
tured for 5–6 days in an incubator. The embryo is then ei-
ther immediately placed into the patient by intrauterine
transfer or, more commonly, frozen until future use
when the recipient has had additional time to recover
from the egg retrieval procedure. The embryo can subse-
quently be thawed and transferred, hopefully resulting in
successful implantation.
The best-practice process of an IVF cycle under cur-
rent international standards3 inherently provides direct
access to germ cells and embryo to deliver the CRISPR-
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Cas genome editing machinery (Fig. 1A). In particular,
the ICSI procedure provides a great avenue to codeliver
sperm and genome editing molecules into the egg, to
edit the genome of the resulting zygote.4
Can GGE be performed without IVF? Some hypothet-
ical strategies for GGE have been suggested that do not
involve classical IVF. For example, sperm or eggs are
edited in a dish and replaced into the female reproductive
system to attempt a subsequent ‘‘natural’’ fertilization.
Alternatively, gonads are targeted directly, in hopes of
modifying germ cells in their native location. In another
version, germline stem cells are isolated from gonads,
modified in a dish, and grafted back into ovary or testes.
It is even conceivable to attempt targeting a naturally fer-
tilized zygote by using uterine lavage to isolate it, editing
the zygote in vitro, and transferring it back into the fe-
male. Either of those methods would most likely still
be performed in the setting of a fertility clinic. Ulti-
mately, the likeliest opportunity for application of GGE
techniques will occur during conventional IVF. Not sur-
prisingly, all published studies on human GGE so far
have been carried out in IVF-generated zygotes.4–10
Avoiding Inherited Genetic Disorders
with Preimplantation Genetic Testing
The field of IVF has made tremendous advances since its
inception 40 years ago, perhaps none bigger than the in-
troduction of preimplantation genetic testing (PGT, pre-
viously known as PGD/PGS). Its goal is to identify the
genetically healthy embryos in a patient’s cohort with
highest chances of implantation.
The role of PGT in avoiding transmission of familial ge-
netic disorders has been greatly undervalued in scientific
and public discourse surrounding GGE. Conceptually it
FIG. 1. Overview of the IVF process. (A) Typical workﬂow of an IVF cycle. (B–E) Biopsy collection for subsequent
PGT. (B) Human blastocyst stage embryo with ICM at the 9 O’clock position next to a holding pipette. (C) Pulses
from a laser (concentric red/yellow circles show the cross hairs) create an opening in the ZP at the 3 O’clock
position, and a biopsy needle is inserted and guided to the TE tissue. (D) A clump of cells is extracted through the
ZP opening by suction applied by the biopsy pipette, and laser pulses are directed at exposed cell–cell junctions.
(E) The separated 5–10 cell biopsy is collected for subsequent genetic analysis. The blastocyst is vitriﬁed until
further use. Scale bars = 50 lm. ICM, inner cell mass; IVF, in vitro fertilization; PGT, preimplantation genetic testing;
TE, trophectoderm; ZP, zona pellucida.














































involves isolating a cell or group of cells (the biopsy)
from the developing embryo to analyze its genetic con-
tent, using it as a proxy for the entire embryo.3 Common
PGT techniques currently require the isolation of a 5–10
cell biopsy at the blastocyst stage from the trophecto-
derm, the precursor tissue of the placenta (Fig. 1B–E).
The isolated cells’ DNA content is subsequently ampli-
fied and analyzed. This has proved safer to the embryo
(i.e., less impact on viability) than earlier PGT meth-
ods collecting a single cell at the cleavage stage, and
in addition provides more genetic material for analy-
sis, which decreases the likelihood of erroneous or no
results.11
Patients with a familial disorder can apply PGT for
monogenic (-M) traits to identify embryos that have
inherited the causative allele among their cohort of
IVF-generated embryos and eliminate them from consid-
eration for intrauterine transfer and possible implantation
(Fig. 2A). The technique utilizes linkage analysis and/or
direct sequencing of the causative mutation,12,13 and is in
principle adaptable to any monogenic disorder, gene var-
iants with increased disease risk, late-onset disorders, and
mitochondrial DNA (mtDNA) mutations.11
In the past two decades, PGT-M has been performed in
at least 100,000 IVF cycles worldwide,11 for >400 differ-
ent single-gene disorders.12 Most recently, PGT has been
designed to identify complex (polygenic) conditions,
such as congenital diabetes or cardiomyopathies, in a
test involving the calculation of polygenic risk scores
called PGT-P.14 This test aims to provide relative risk re-
duction through genetic testing and identification of sig-
nificant outliers. It calculates risk scores for complex
conditions in embryos, not unlike services offered by
direct-to-consumer genetic profiling companies. (Given
FIG. 2. Scenarios requiring PGT or GGE to prevent transmission of genetic disorders. (A) PGT requires collecting a
biopsy of the embryo, which is tested for the mutation causative of the hereditary condition. The embryos in an
IVF patient’s cohort that do not inherit the mutation are selected for transfer and implantation. (B) PGT is the
preferred method whenever embryos can be generated that are free of the mutation. When one of the parents is
homozygous for a dominant disorder, or both parents are homozygous for a recessive disorder, all resulting
embryos are affected, and GGE can be used to correct the mutation. GGE, germline genome editing; IVF, in vitro
fertilization; PGT, preimplantation genetic testing.














































the novelty of this approach, medical societies have not
yet formulated ethical statements specifically addressing
polygenic testing and risk score assessment in embryos.)
Other versions of PGT can be used to detect chromo-
somal abnormalities, from aneuploidy with PGT-A to
structural rearrangements with PGT-SR.
Together, these various PGT formats are being
employed in 38% of the 245,000 IVF cycles taking place
each year in the United States,15 of which 10% are PGT-
M probing for monogenic disorders.16
The Ethics of PGT Versus GGE
Although the clinical goals of PGT and GGE to prevent
the inheritance of genetic disease are similar, the ethics
relevant to the two technologies is irrefutably different.
In a recent position statement, the Ethics Committee
of the American Society for Reproductive Medicine
(ASRM) suggests that the use of PGT is ethically justi-
fied for severe congenital as well as adult-onset con-
ditions, and furthermore endorses the use of PGT for
conditions of lesser severity or penetrance if no safe,
effective interventions are available.17 An important
distinction between GGE and PGT is that the process
of PGT does not create a new genetic trait. The constel-
lation of genes present in the embryo selected for trans-
fer after PGT screening could also have occurred if the
couple had conceived naturally.
Unlike the practice of GGE, PGT obviously carries no
risk of undesirable off- and on-target effects and no
chance of introducing genetic mosaicism. However, one
possible ethical argument in favor of GGE versus PGT
is that, within the IVF industry, it remains standard prac-
tice to dispose of PGT embryos identified with a mutant
allele or chromosomal defects. One could argue that GGE
could repair and salvage these otherwise discarded em-
bryos. However, utilizing GGE would not circumvent
disposition of embryos, as it would remain unlikely that
every embryo within an IVF cycle will always be trans-
ferred; often IVF patients give rise to supernumerary em-
bryos that are routinely cryopreserved or discarded as
part of IVF cycle management.
From a regulatory perspective, PGT in the United
States has remained largely free from intervention by
the U.S. Food and Drug Administration (FDA). Not so
GGE, which clearly falls under FDA’s domain as it claims
‘‘regulatory authority over genetically manipulated cells
and/or their derivatives.’’ Although somatic gene thera-
pies have already been approved by the FDA with several
trials under way, an FDA-approved GGE therapy is cur-
rently impossible.18 A renewable provision of the Con-
solidated Appropriation Act, initially signed into law in
2016, explicitly prohibits the FDA from reviewing appli-
cations for ‘‘an exemption for investigational use of a
drug or biological product.in which a human embryo
is intentionally created or modified to include a heritable
genetic modification.’’19 This moratorium in effect has
been renewed every year since and its short- and long-
term future are unclear. Editing the genome of a human
embryo without uterine transfer for research purposes is
still legal in the United States, although ineligible for
public funding.19
Numerous position statements have been issued con-
cerning GGE,20 and different ethical ramifications are cur-
rently being explored, but here we specifically consider the
unmet medical need that GGE would address. When is
GGE a valid medical alternative to PGT? Which is the
more appropriate treatment? Does the magnitude of
the medical demand for GGE justify its practice? Given
the numerous technical, regulatory, and ethical concerns
about the possibility of applying GGE in assisted repro-
duction, we should proceed very carefully. GGE would
be warranted only if there is real and significant demand
for the technology that could not be satisfied by other
means.21
Estimation of GGE Demand for Hereditary Disorders
Let us consider a hypothetical scenario: if a family suffers
from an inherited disease, should their IVF plan be lim-
ited to PGT screening for nonaffected embryos, or are
there circumstances when we should consider correcting
their embryos with GGE?
In recessive monogenic disorders, each embryo con-
ceived from two heterozygous parents will have a 1-in-
4 chance of inheriting two copies of the unaffected allele
and a 1-in-4 chance of being homozygous for the mutant
allele. In a typical case, the unaffected embryos can be
chosen for uterine transfer (Fig. 2B). Statistically, there
will be some instances when every embryo of such a pa-
tient’s IVF cycle might carry the mutation in question.
Before considering GGE to correct the existing embryos,
the couple could elect to undertake another IVF cycle
with the hope of producing unaffected embryos. A typical
IVF cycle will produce three to five blastocysts, but eight
or more are not uncommon. In our center, the average
number of blastocysts per cycle is 4.2 across all ages
and indications, meaning that the likelihood of conceiv-
ing an unaffected embryo increases with subsequent mul-
tiple IVF cycles. A large study from a genetic testing
laboratory reported that a mere 7.1% of all cycles with
PGT-M resulted in no genetically normal embryos avail-
able for transfer.22 Those unlucky patients could subse-
quently do another IVF cycle and cast the die anew.
Each additional IVF cycle carries its costs, as well as a
physical and emotional toll on patients. However, PGT to














































screen embryos will most likely be easier, cheaper, and
safer to perform than GGE. When implementing GGE,
one would likely first need to perform PGT to test which
embryos inherited the mutation, and then again after
GGE to confirm that the correction happened. Each in-
tervention affects the viability of embryos, meaning a
substantial increase in costs and risks. Unless methods
are developed to efficiently edit all cells in a multicel-
lular embryo, one is confined to performing the GGE
intervention at the zygote stage, meaning that prior ge-
netic testing is impossible (the process destroys the cell
being analyzed). Genome editing molecules would need
to be applied ‘‘blindly’’ into every zygote, affected and
unaffected alike. Considering this and the possibility
for off-target effects of GGE, we submit that hereditary
conditions will continue to be handled preferentially by
screening embryos with PGT over correcting them with
GGE.
Scenarios Favoring GGE over PGT
Do situations exist when PGT does not work? The answer
is emphatically ‘‘Yes.’’ PGT is pointless if dealing with a
recessive disorder when both parents are homozygous
mutants, as all resulting embryos will be homozygous
mutants as well. Only GGE would prevent transmission
of the disorder. Similarly, if there is a familial autosomal
dominant disorder and one or both parents are homozy-
gous for the mutant allele, every embryo will inherit at
least one copy of the mutation and be affected (Fig. 2B).
But what is the frequency of those scenarios?
Previous commentaries have broached the sub-
ject,21,23,24 but a thorough analysis based on genetic epi-
demiology is warranted. In an effort to answer that
question, we used published prevalence data for the
most common genetic disorders in the United States to
project how many conceptions would benefit from GGE
per year on a national level (Table 1).
For common recessive disorders such as cystic fibrosis
(CF), sickle cell disease (SCD), or Tay–Sachs, we calcu-
lated the chances of two homozygous mutant individuals
forming a reproductive couple by random chance (see
Some Caveats section for assumptions in these projec-
tions). For example, the number of people living in the
United States with CF who are homozygous for CFTR
mutations is estimated at 30,000, which means the prev-
alence in the general population is roughly 1 in*10,000.
The likelihood of two CF patients forming a couple is 1 in
*10,000 (assuming each affected individual pairs with a
single mate).2 We estimate that in the United States, there
is only one couple of reproductive age at any given time
where both partners are homozygous for CF mutant al-
leles (the exact calculated value is 1.26 couples). Consid-
ering the current data for the population percentage based
on reproductive age, average fertility rate per woman,
and range of reproductive years, we can estimate the
number of conceptions each year in the United States
for which GGE would be applicable. For CF, this number
is negligible—a mere 0.065 cases per year—
indicating we could anticipate that the need for GGE
treatment to prevent the transmission of CF would
occur only once every 15 years, with all other CF cases
relying on PGT.
We performed calculations for other recessive genetic
disorders and considered instances for which assortative
mating and variable ethnical prevalence are relevant,
such as SCD in the African American population and
Tay–Sachs in Ashkenazi Jews. The number of projected
cases is remarkably small for all of the most common
single-gene recessive disorders,22 totaling fewer than a
dozen clinical cases of estimated children born per year
in the United States that might hypothetically benefit
from GGE (Table 1).
A more complex inheritance pattern is found in a-
thalassemia, possibly the most common severe genetic
disorder in the general U.S. population, due to the four al-
leles on two HBA genes. If one or two alleles are mutant,
the phenotype is generally asymptomatic. When three al-
leles are mutant, the condition is known as hemoglobin
H (HbH) disease and patients often suffer from ane-
mia, hepatosplenomegaly, and jaundice. Harboring four
mutant alleles causes the condition hemoglobin Bart’s
hydrops fetalis syndrome (BHFS), which is almost al-
ways lethal during gestation or shortly after birth. In
the literature, 69 cases of BHFS have been documented
that have survived past infancy, with 18 instances of sur-
vival past 10 years of age.25 The demand for GGE for a-
thalassemia is, therefore, virtually nil, as there will likely
never be a couple with BHFS intending to procreate. In
the case that two HbH patients would like to have chil-
dren, one in four embryos generated would be asymp-
tomatic carriers, one in two embryos would have HbH,
and one in four embryos would die in utero with
BHFS.26 In this case, utilizing PGT to facilitate selection
of an asymptomatic carrier would likely be favored over
attempting GGE.
Homozygosity for severe dominant disorders is almost
always embryonically lethal, making the number of such
individuals virtually nonexistent in the general popula-
tion. For example, the number of cases homozygous for
Huntington’s disease is in the dozens.23 There have
been 13 recorded patients homozygous for myotonic dys-
trophy type 1.27 Homozygotes for mutations causing
neurofibromatosis type 1 have never been documented.28
Achondroplasia, one of the most common dominant































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































disorders, is caused by a mutation in FGFR3. When het-
erozygous, it causes dwarfism, but is considered uni-
formly fatal when homozygous, and only a handful of
cases are reported to have survived into early child-
hood.29 Therefore, the projected annual national demand
of GGE for dominant disorders approaches zero, as PGT
is applicable to identify nonaffected embryos in virtually
all cases.
PGT is also appropriate for cases of X-linked disor-
ders. Female carriers of a recessive X-linked disorder
have a one in four chance with each pregnancy to have
a carrier daughter, a one in four chance to have a noncar-
rier daughter, a one in four chance to have a son affected
with the disease, and a one in four chance to have an un-
affected son. PGT can identify affected male embryos. In
cases where the mother is homozygous for the mutation,
all the male offspring would inherit a mutant copy of X.
Here again, just with autosomal dominant disorders, the
prevalence of homozygosity for X-linked disorders is re-
markably low.30 For example, Duchenne muscular dys-
trophy has never been identified as homozygous.31
Hemophilia A, which affects 1:5,000 male births, has
only ever been documented as homozygous a few
times.32–35 Fragile X syndrome, considered a dominant
X-linked disorder, is characterized by amplification of a
trinucleotide repeat, and has only been described as ho-
mozygous in the premutation form, not the fully ampli-
fied allele.36
One clinical situation that would benefit from genome
editing is a male affected by a dominant X-linked disor-
der who wishes to conceive children. His male embryos
will be disease free by default. But a daughter would un-
doubtedly inherit his affected X chromosome. Such a cir-
cumstance prompts a different ethical discussion
revolving around gender selection, and specifically the
justification for wanting a female child that must be ge-
netically altered rather than choosing a healthy male.
Here again, due to PGT, the number of cases who
would require GGE is extremely small.
What about less severe hereditary conditions? It has
been suggested that couples with congenital hearing
loss, which affects 1 in 500 individuals, might consider
GGE to have a hearing-enabled child.23 Deafness is ge-
netically heterogeneous with >1,000 mutations identified
in >90 genes, but recessively inherited single-gene muta-
tions in GJB2 are responsible for over half of all cases.37
Historically, deafness has been a prime example for assor-
tative mating. In the 1970s, 80–90% of people with pro-
found deafness in the United States married another deaf
person.38 It is estimated that 1 person in 4,500 is homozy-
gous mutant for GJB2.39 Assuming that all GJB2-mutant
homozygotes of reproductive age intermarried and repro-
duced at general rates, there could be a potential 837 con-
ceptions nationally per year that would benefit from
editing GJB2, which is a sizable number.
However, the fact that deafness is a treatable condition
invalidates this projection. The introduction of cochlear-
implant technology has profoundly altered the mating
structure of the deaf population.40 By facilitating oral
communication and educational mainstreaming, practi-
cally all deaf children of hearing parents are redirected
into the hearing mating pool.40 This is an example in
which treatment might obviate the need for GGE and
its associated risks. We predict that GGE will find little
demand in less severe or treatable genetic conditions,
considering medical necessity and alternative interven-
tions. This was also one of the main criticisms of the only
alleged case of human GGE resulting in births reported to
date, whereCCR5was mutated to diminish chances of pos-
sible HIV infection—proven strategies already exist for the
prevention of perinatal transmission of HIV.41
GGE might be the only strategy for IVF patients who
carry a genetic condition but have conceived only af-
fected embryos and are precluded from initiating addi-
tional IVF cycles because of advancing age, disease, or
cost. Of the annual *100,000 IVF cycles in the United
States accompanied by PGT,15 the fraction using PGT-
M for single-gene disorders is estimated at 10%.16 Of
those, 7.1% are estimated not to generate any normal em-
bryos,22 resulting in*7,100 cycles. Judging from obser-
vations in our IVF center, we estimate <1% of patients
not being able to perform a subsequent IVF cycle for
PGT-M when desired. Hence, we project there to be at
most 71 cases per year in the United States who would
benefit from GGE for this particular scenario, if all pa-
tients elected to pursue that procedure.
It should be noted that the unicellular zygote cannot be
tested for a genetic disorder without destroying it. It is,
therefore, not feasible to screen zygotes for a mutant al-
lele and then attempt to edit that allele. GGE at the zygote
stage makes sense only when there is previous knowledge
of that zygote’s genetic makeup, as when the complement
is deduced from homozygosity for the mutant allele in
one or both parents. One exception is with maternal het-
erozygosity, as one can attempt deducing the status of the
zygote by analyzing polar bodies, which are the products
of meiosis. Although historically there has been some
limited success, this practice produces notoriously high
amounts of false positives and negatives. The state of het-
erozygosity in the mother would permit conventional
PGT screening for embryos not having inherited the al-
lele, precluding the need for GGE. Therefore, even
when there would be demand for GGE, the gene editing
machinery would only be administered later in














































development, likely at the blastocyst stage when most
PGT takes place and affected embryos are identified.
However, the expertise does not yet exist to deliver
CRISPR-Cas to all 64–128 cells of a blastocyst and pre-
vent any incidence of the potential medical risks associ-
ated with resultant mosaicism.
Together, our analysis suggests that the true clinical
demand for GGE for single-gene hereditary disorders is
exceedingly small. We estimate that GGE could at
most benefit 100 births per year in the United States,
when all eligible patients opted for the procedure.
Use of GGE in mtDNA Disease
mtDNA disease is relatively common, with an estimated
prevalence of 1 in 5,000,42 and causes severe and debil-
itating genetic disorders such as Leigh disease, Kearns-
Sayre syndrome, or Mitochondrial encephalomyopathy,
lactic acidosis, and stroke-like episodes (MELAS). Most
mtDNA mutations occur de novo, and maternal transmis-
sion of mtDNA disease is rare. There are an estimated
*800 pregnancies per year in the United States at risk
of maternal transfer of mutant mtDNA.43 Owing to the
multicopy nature of mtDNA, mutant mtDNA often exists
in a mix with normal mtDNA in a cell, a state known as
heteroplasmy. In most cases, PGT-M can be designed to
identify and quantify mutations in mtDNA to deselect em-
bryos with high mutation load. The circumstances in
which PGT-M is not useful are those in which there is
homoplasmy of mutant mtDNA, or when the patient is
only capable of producing heteroplasmic embryos with
high mutation load. In those instances, GGE might reduce
the mutation load by correcting mutations in as many
mtDNA copies as possible. Even with such a treatment,
GGE would need to be proven more effective and safer
than the alternative treatment of mitochondrial replace-
ment therapy.44 Taking these factors into account, we
conclude that the U.S. annual demand for GGE for
mtDNA disorders might be in the low dozens.
Can GGE Cure Embryonic Aneuploidy and Other
Chromosomal Abnormalities?
PGT-A and PGT-SR, which test embryos for chromo-
somal abnormalities, are now performed in >30% of
IVF cycles in the United States and growing.15,16 Some
of those instances are for familial conditions, for which
there is a risk of inheriting a chromosomal abnormality.
However, PGT-A/PGT-SR is mostly utilized as a screen,
even when both parents are chromosomally normal.
Chromosomal abnormalities are common de novo events
in naturally conceived embryos as well as in those gener-
ated by IVF,11 and embryos that carry chromosomal ab-
normalities are developmentally compromised and often
fail to implant. When implantation does occur, the preg-
nancy often results in miscarriage. In the few instances
wherein they make it to birth, the offspring is bound to
harbor chromosomal conditions ranging fromwhole chro-
mosome monosomies or trisomies (e.g., Down, Turner,
or Edwards syndromes), subchromosomal segmental de-
letions or duplications (e.g., Cri-du-Chat, Angelman, or
Prader–Willi syndromes), or rearrangements that can
lead to a range of conditions. PGT-A/PGT-SR facilitates
the deselection of such embryos before intrauterine trans-
fer, and numerous randomized controlled trials and ob-
servational studies have reported a significant increase
in clinical success rates when embryos classified as
normal/euploid are used in comparison with blindly
selecting embryos for transfer into the patient.45–47
Importantly, the observed rates of embryo aneuploidy
increase with advancing maternal age due to errors of mei-
osis during oocyte maturation, a process that becomes
more error prone over time.48 On average, rates of aneu-
ploidy increase from 30% of IVF embryos in women in
their early 30s to nearly 90% for women aged 44 years
and above.49 This correlation between maternal age and
proportion of aneuploid embryos means that classical Men-
delian calculations do not apply. In contrast with hereditary
single-gene disorders wherein there is a high likelihood of
conceiving a genetically normal embryo at each IVF cycle,
a patient with advanced maternal age has an elevated risk
of producing only aneuploid embryos even after multiple
IVF cycles. In addition, a large study analyzing >15,000
IVF embryos has shown that there is even a subset of youn-
ger patients also only capable of generating aneuploid em-
bryos,49 possibly due to faulty cell cycle mechanisms in
those patients. When a couple is only able to generate
chromosomally abnormal embryos, even after repeated
IVF cycles, the result would often be their abandon-
ment of infertility treatment altogether.
Could GGE correct chromosomal abnormalities in em-
bryos, such as erasure of the additional chromosome
present in trisomic embryos? Even though this technol-
ogy does not yet exist, intriguing new data have emerged
with proof-of-concept experiments targeting and deleting
of entire chromosomes.50,51 What is the potential clinical
demand for that procedure? Internal data from 1,769 IVF
cycles at our IVF center indicate that *20% of initial
cycles produce only aneuploid embryos, and a subsequent
cycle for those patients has *60% chance of containing
only aneuploid embryos. We also observe that *100%
of patients who produce only aneuploids after three cycles
discontinue their IVF treatment. Extrapolating those fig-
ures to the*245,000 IVF cycles currently performed an-
nually in the United States,15 we estimate that *17,600
patients would benefit from GGE of aneuploid embryos.














































A different application for this kind of GGE is for in-
dividuals with Robertsonian translocations. Such individ-
uals are typically healthy except for their increased
chances of generating embryos with aneuploidies. Rob-
ertsonian translocation 21q; 21q is particularly problem-
atic, since 100% of resulting embryos have trisomy 21
and, therefore, Down’s syndrome if carried to term.52
Since PGT-A for screening is not beneficial, this situation
would meet the requirement for unmet medical need.
It is to be noted that this practice would not be consid-
ered GGE in the classical sense, because the target is not
the zygote but a 64-128-cell blastocyst. Unless tech-
niques are developed to target every cell in the blastocyst,
the result will inevitably be mosaicism. Interestingly, re-
cent data have shown that blastocysts classified by PGT-
A as chromosomally mosaic (harboring a mix of euploid
and aneuploid cells) can result in implantation and healthy
pregnancies, although with significantly lower success
rates than blastocysts classified as euploid.53–55 To date,
*300 babies born from transferred mosaic embryos
have not presented medical complications of any
kind.53–55 Evidence from mouse and human embryology
indicates that in a mosaic embryo euploid cells dilute out
aneuploid cells as the latter preferentially die off or divide
at slower rates during development.55,56
Deleting an extra chromosome when trisomy is present
would typically imply the creation of uniparental disomy,
since the GGE machinery would need to target the chro-
mosome that is dissimilar and contains differentiating
DNA sequences. The implication is that the remaining
two chromosomes would stem from the same parent, po-
tentially creating epigenetic consequences with medical
manifestations. Testing parental genomes, polar bodies,
and deep sequencing of the TE biopsy in PGT-A might
help identify exploitable differentiating regions between
duplicated chromosomes. More research is needed in
this field, and careful consideration will have to be
given to what regions/chromosomes can be targeted to
rid an embryo of aneuploidy.
In summary, the prospect of GGE for chromosomal
correction could have a tremendous impact on IVF pa-
tients, although many technical advances and much
more research are needed.
Some Caveats
We must note some significant assumptions within our
calculations. Several of the genetic disorders described
here shorten life expectancies and alter life conditions to
the point of skewing statistics regarding fertility for
these populations. For example, the median age of sur-
vival for SCD is 48 years, for CF it is 33.4 years, and
for Tay–Sachs it is 4–5 years. The likelihood of two af-
fected individuals meeting is not entirely up to chance
(as the simple calculations suggest). Having the same dis-
order could make it more likely for two patients to come
together to form a couple (assortative mating); individuals
with a particular condition are more likely to meet others
with the same condition through societies, associations,
and help groups. In contrast, certain genetic disorders af-
fect the immune system and increase risk of infection,
making it risky to interact with other patients of the
same condition. For example, CF patients are recommen-
ded to maintain a minimal distance of 2m from each other
at all times due to the risk of bacterial cross-infection.57
The incidence of genetic disorders is also altered by
sociocultural and ethnicity factors such as consanguinity,
endogamy, and high prevalence in certain groups, such as
Tay–Sachs or SCD. Penetrance and variable expressivity
have been disregarded for simplicity. Mutations causing
disorders with treatable symptoms such as hemochroma-
tosis, or mutations that increase disease risk such as
BRCA1/2, were generally excluded from this analysis
as testing for those conditions is not common or remains
controversial; performing GGE for those factors is even
more unlikely. Importantly, our calculations using pub-
lished prevalence data assume that all cases of a genetic
disorder are inherited, although a substantial percentage
of de novo mutations cases do occur for particular types
of inherited disorders. Taken together, these assumptions
suggest that our projections are likely inflated, and the ac-
tual demand of GGE targeting heritable genetic disorders
is probably even lower than the figures already presented.
Nonmedical Enhancements
We have not considered the hypothetical demand for
GGE to introduce genome edits of a nonmedical nature
for enhancement. The prospect of ‘‘designer babies’’
whose DNA is sculpted by GGE to control features
such as intelligence, height, and longevity would require
the development of safe methods to edit dozens, hundreds,
or maybe thousands of loci in the genome. Complex traits
are multifactorial and the full set of involved genes re-
mains unknown. PGT-P could potentially be used to
screen embryos for such enhancements, for example, rank-
ing the embryos in a patient’s cohort for predicted height.
Aside from the obvious ethical concerns, we believe the
actual demand for such nonmedical screening will be neg-
ligible. IVF laboratories have had the capability of using
PGT to select for traits such as eye color, for example,
but this has not become common practice.16
Conclusions
Our calculations should not be considered exact predic-
tions of the potential demand for GGE. They are intended














































to provide some calibration of expectations. GGE is inev-
itably entwined with IVF, a medical field that has long
dealt with screening for familial genetic disorders using
PGT. Couples in which one or both partners are affected
by a genetic disorder would necessarily need to undergo
IVF whether the strategy to prevent propagation of the
causative allele involved GGE or PGT. Given the choice,
we believe that PGT will always be preferred.
Our projections show there are extremely few in-
stances for which GGE will be the only option, such as
when both parents are homozygotes for a recessive con-
dition or at least one parent is homozygous for a domi-
nant condition. We do not intend to downplay the
importance of those rare cases and patients. Nonetheless,
the actual magnitude of the demand for GGEmust be part
of the conversationwhen debating ethical and legal frame-
works. However, we suggest that aneuploidy might be a
much larger issue than previously considered, as we pre-
dict there will be many potential beneficiaries of chromo-
somal editing in embryos if safe technologies for that
purpose can be developed.
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